about
Somatic SF3B1 mutation in myelodysplasia with ring sideroblastsCombining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stabilityAberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7qDisruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cellsIL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cellsLenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterationsGene expression profiling in the myelodysplastic syndromes.Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signalingInhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis.Clinical and biological implications of driver mutations in myelodysplastic syndromes.Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.Advances in the 5q- syndrome.Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.5q- syndrome.Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).The molecular pathogenesis of the myelodysplastic syndromes.Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.Application of CRISPR/Cas9 genome editing to the study and treatment of disease.Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.Recent Advances in the 5q- Syndrome.Application of genome editing technologies to the study and treatment of hematological disease.Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.
P50
Q27851675-15E3E561-3B58-42AA-88AD-8143ED4F8EBDQ30883788-54AEE76E-31DB-4388-B3B4-D3AF2B80C866Q31171330-16F44133-5267-4011-9113-2AB8F17D1042Q33327379-E03A2C66-FC96-41DF-9313-6C2BAF91DF67Q33595674-F9FC54F3-9648-4DAC-A672-24A760069E11Q33987086-392B9CF5-E44C-4274-A0DB-FAE77640B2C6Q34388734-AAE2A388-4B5F-4E51-A3A2-D2F9D6B1AC13Q34637945-C7D06710-9F23-4AC3-82AB-4952BBA56AD9Q35107545-1946F859-B628-4429-8F0F-8EA0E9861AEAQ35603613-9351B71D-13E8-4B88-9647-05FE61BD8FC5Q35607293-862E2920-8ADE-49A0-934A-593B80218D58Q35844148-612667DE-2294-41A3-B2B9-A9A068909B6CQ36163066-613C167D-9089-43C8-8999-4B4063BCBF29Q36220721-D3D7E22A-B15F-4E4F-A16E-021D1456F5ADQ36221521-7B0EB145-40AF-488C-951E-D8C27105C2B4Q36737106-BFF3A662-7E90-4031-8131-9A8C46EB0D44Q36761526-05D79BDC-A88E-461C-BCD1-31CB7A8A1170Q36941110-496275B8-93DE-45CA-BF88-5D919CE964EBQ37218274-3BB21F2E-4E69-45BE-BB9F-06305D1556DFQ37331556-269CACA1-6F3A-4B02-B062-09C2603CB928Q37334716-C44F90EF-FDCC-448F-8163-65C39D404CE8Q37377901-CCA000E5-9680-4720-B482-92E249C0738FQ37470872-F6BDDB12-556B-4CDF-BC58-D0D21BBC6AC4Q37781950-786CF8A4-1AFF-4EE9-B314-0ECEC8E55FA2Q37935217-EBB40BC5-503E-4AF2-B306-552C386295AEQ38008749-465A7EB1-2E56-490E-8D83-3348E277F984Q38049004-06EA2EF6-CE91-4C28-83E1-070EE162ACFCQ38147839-CFA28716-B5B7-42EB-BEB9-B10745AAAFC7Q38278197-0E36647E-94F5-425F-9391-C38CB87D1F6BQ38341998-DBFB7441-B990-4AEB-BF3F-2DB9387EFF2EQ38354139-02771781-7E89-45B9-9646-E3411E46C9A5Q38397580-7725432A-100C-4018-BC81-ADE2F5A7EAF7Q38507121-354F8AAA-C75F-45AF-A322-888F9549C3C6Q38527837-81929D6F-AEBC-4097-8397-0C7A2B61785FQ38598463-4E5E454B-EB74-4663-B4DB-1ABDD3C61BA7Q41590597-0E1135CE-D90F-4FE2-8DAD-9F31221BEDC5Q42588518-A16E445B-E7FD-4505-8136-3A41E11289C0Q43090535-5C3443C4-997E-436B-9004-C8A0AA306C7BQ43100101-C6790341-4F9A-401C-8505-DDB4C0E9F736Q43443310-BF34C08C-A505-4E95-8F57-9D5DE8110E0A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrea Pellagatti
@ast
Andrea Pellagatti
@en
Andrea Pellagatti
@es
Andrea Pellagatti
@nl
type
label
Andrea Pellagatti
@ast
Andrea Pellagatti
@en
Andrea Pellagatti
@es
Andrea Pellagatti
@nl
prefLabel
Andrea Pellagatti
@ast
Andrea Pellagatti
@en
Andrea Pellagatti
@es
Andrea Pellagatti
@nl
P106
P31
P496
0000-0002-6122-0221